5-ethyl-2′-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil

被引:6
作者
Kralovánszky, J
Katona, C
Jeney, A
Pandi, E
Noordhuis, P
Erdelyi-Toth, V
Ötvös, L
Kovács, P
Van der Wilt, CL
Peters, GJ
机构
[1] Natl Inst Oncol, Dept Clin Res, H-1525 Budapest, Hungary
[2] Semmelweis Univ Med, Inst Pathol & Expt Canc Res 1, H-1085 Budapest, Hungary
[3] Free Univ Amsterdam Hosp, Dept Med Oncol, Amsterdam, Netherlands
[4] Hungarian Natl Acad Sci, Cent Res Inst Chem, H-1026 Budapest, Hungary
[5] Univ Med Sch, Inst Pharmacol, H-4012 Debrecen, Hungary
基金
匈牙利科学研究基金会;
关键词
5-fluorouracil; 5-ethyl-2 '-deoxyuridine; modulation; antitumour activity; pharmacokinetics;
D O I
10.1007/s004320050333
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present studies was to elucidate the effects and optimal modulatory conditions of 5-ethyl-2'-deoxyuridine (EtdUrd) on the antitumour efficacy. pharmacokinetics and catabolism of 5-fluorouracil (5-FU) on Colon-26 and Colon-38 murine tumours. HPLC and GC-MS techniques were used to measure the concentrations of 5-FU, dihydro-5-fluorouracil, EtdUrd, 5-ethyluracil and uridine in the plasma and that of 5-FU and 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) in the tumours. It was shown that EtdUrd, given 1 h before 5-FU, selectively enhanced the antitumour action of 5-FU, without significantly increasing its toxic side-effects, thus resulting in an approximately three times higher therapeutic index. Pharmacokinetic studies revealed that 1 h after 400 mg kg EtdUrd administration - i.e. at the time of 5-FU treatment - the plasma concentration of EtdUrd was 269 mu M, and that of 5-ethyluracil, as the major metabelite of EtdUrd, was 421 mu M. It is of interest that EtdUrd pretreatment did not change the maximal plasma concentration of 5-FU; however, the half-life of the terminal elimination increased from 114.5 min to 171.2 min and thus the mean residence time of 5-FU rose significantly (P < 0.05). After the combined treatment, the maximal concentration of dihydro-5-fluorouracil in the plasma decreased from 61.06 mu M to 29.70 mu M (P < 0.01). The intratumoral concentrations of 5-FU were 34%-158% higher 6-96 h after the combined treatment than after the single 5-FU treatment. EtdUrd also caused a moderate increase in the intratumoral level of FdUMP. It is noteworthy, that EtdUrd increased the endogenous uridine concentration in the plasma from 18 mu M to a maximum of 249 mu M, and the level remained high for longer than 6 h. The present studies indicate that EtdUrd enhances the therapeutic index of 5-FU by reducing the catabolism, prolonging the plasma and intratumoral concentrations of 5-FU and, at the same time, offering protection to normal organs by increasing the endogenous uridine level.
引用
收藏
页码:675 / 684
页数:10
相关论文
共 45 条
[1]   5-ETHYNYLURACIL (776C85) - A POTENT MODULATOR OF THE PHARMACOKINETICS AND ANTITUMOR EFFICACY OF 5-FLUOROURACIL [J].
BACCANARI, DP ;
DAVIS, ST ;
KNICK, VC ;
SPECTOR, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11064-11068
[2]  
BAGRIJ T, 1993, ANTICANCER RES, V13, P789
[3]   Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase [J].
Baker, SD ;
Khor, SP ;
Adjei, AA ;
Doucette, M ;
Spector, T ;
Donehower, RC ;
Grochow, LB ;
Sartorius, SE ;
Noe, DA ;
Hohneker, JA ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3085-3096
[4]  
BURTLES SS, 1995, EUR J CANCER, V31A, P408
[5]  
CAO SS, 1994, CANCER RES, V54, P1507
[6]  
CodacciPisanelli G, 1997, CLIN CANCER RES, V3, P309
[7]   EFFECT OF URIDINE DIPHOSPHOGLUCOSE ON LEVELS OF 5-PHOSPHORIBOSYL PYROPHOSPHATE AND URIDINE TRIPHOSPHATE IN MURINE TISSUES [J].
COLOFIORE, JR ;
SAWYER, RC ;
BALIS, ME ;
MARTIN, DS .
PHARMACEUTICAL RESEARCH, 1989, 6 (10) :863-866
[8]  
DESGRANGES C, 1986, CANCER RES, V46, P1094
[9]  
Fischel JL, 1995, CLIN CANCER RES, V1, P991
[10]  
GAURI KK, 1981, ANTIVIRAL CHEMOTHERA, P235